-

BioTek reMEDys Offers New COVID-19 Therapies

Through Agreement with TidalHealth, BioTek reMEDys will Support High-Risk COVID-19 Positive Patients through the Administering of Infusions of New Monoclonal Antibodies

SALISBURY, Md.--(BUSINESS WIRE)--BioTek reMEDys and its subsidiaries have entered into an agreement with TidalHealth to manage an infusion suite specifically for the new monoclonal antibodies produced by Eli Lilly and Regeneron. These drugs are used specifically for the treatment of patients that have additional risk factors for developing more severe cases of COVID-19.

The infusion suite, near TidalHealth’s hospital in Salisbury, MD, opened and began treating patients in mid-December.

The importance of and demand for providing these treatments, under the FDA’s Emergency Use Approval, led to the collaboration between BioTek reMEDys and TidalHealth to open the infusion suite quickly and with the utmost safety. The urgency of COVID-19 created an environment for two healthcare organizations to collaborate and utilize each other’s best practices to swiftly achieve an end goal.

“When health services organizations put the patient first and leave their egos out, it becomes possible to collaborate in ways that surpass anything an individual organization can achieve,” said Chai Gadde, CEO and founder of the BioTek group of companies.

From a business operations perspective, the infusion suite was designed to be fluid in its ability to scale up to meet volume demand and to provide other therapies as needed.

About BioTek reMEDys

Founded in 2011, BioTek reMEDys, based in New Castle, DE, has become one of the nation’s largest independent infusion pharmacies focused on home infusion and infusion suites. Delaware entrepreneur, investor and philanthropist Chai Gadde opened the pharmacy to meet the needs of patients who require specialty medications but desire the feeling of an independent neighborhood pharmacy. Its national footprint now includes locations in Houston and Phoenix. For information visit www.biotekrx.com.

About TidalHealth

TidalHealth -- which includes TidalHealth Peninsula Regional, TidalHealth Nanticoke, TidalHealth McCready Pavilion and an expansive physician network with 250 providers in 22 different specialties -- provides a full range of patient-centered services, including neurosurgery, cardiothoracic surgery, joint replacement, emergency/trauma care, comprehensive cancer care, women’s and children’s services, wound care and clinical trials and research as a member of the Johns Hopkins Clinical Research Network. Learn more at tidalhealth.org.

Contacts

Paul Williams
paul@medialinecommunications.com
310/569-0023

BioTek reMEDys


Release Summary
BioTek reMEDys has teamed with TidalHealth to support high-risk COVID-19 positive patients through administering of infusions of new drugs.
Release Versions

Contacts

Paul Williams
paul@medialinecommunications.com
310/569-0023

Social Media Profiles
More News From BioTek reMEDys

BioTek reMEDys Encourages Education and Awareness for Autoinflammatory Conditions

NEW CASTLE, Del.--(BUSINESS WIRE)--BioTek reMEDys, a multi-site national integrated infusion therapy provider focused on providing support to people with rare diseases, is publicly calling for year-round enhanced education and awareness of these rare diseases and conditions. Autoinflammatory diseases refer to problems with the innate immune system’s reactions. Immune cells target the body’s own healthy tissues by mistake, signaling the body to attack them. This can cause intense episodes of inf...

BioTek reMEDys Celebrates the Work of Collaborating Healthcare Professionals During National Interprofessional Healthcare Month

NEW CASTLE, Del.--(BUSINESS WIRE)--In recognition of National Interprofessional Healthcare Month, BioTek reMEDys, a multi-site national integrated infusion therapy provider focused on providing support to people with rare diseases, is publicly calling for awareness of safe medication use for patients with rare diseases and conditions, while celebrating the critical contributions and collaborative spirit of healthcare professionals nationwide, applauding the efforts of those who impact the patie...

BioTek reMEDys Names Neal Fitzpatrick Chief Strategy Officer

NEW CASTLE, Del.--(BUSINESS WIRE)--BioTek reMEDys, a multi-site national integrated infusion therapy provider focused on providing support to people with rare diseases, has named Neal C. Fitzpatrick as its Chief Strategy Officer. Fitzpatrick recently served as Chief Commercial Officer at a biotech company, charged with leading the organization through a period of high growth. Before this, he served as Vice-President of Sales at ADMA Biologics, where he repositioned an essential product from hos...
Back to Newsroom